RESEARCH-USE BIOSIMILAR ANTIBODY
Infliximab
Monoclonal antibody · IgG1
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
TARGETTNFA
YMonoclonal antibody
CATALOGSC-BS-468
CATALOG NUMBERSC-BS-468
MOLECULAR WEIGHTApprox. 145.98 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
Infliximab is a recombinant research-use antibody directed against TNFA.